Healthcare Global Enterprises · NSE: HCG · BSE: 539787

Q2 FY20 results · Jul–Sep 2019

Healthcare Global Enterprises reported revenue from operations of ₹278.46 crore (up 13.5% from Q2 FY19) and net loss of ₹25.26 crore for Q2 FY20 (Jul–Sep 2019), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY20	Q2 FY19	YoY	Q1 FY20	QoQ
Revenue from operations	278.46	245.32	+13.5%	268.88	+3.6%
Other income	1.52	2.26	−32.7%	1.30	+16.9%
Total income	279.98	247.58	+13.1%	270.18	+3.6%
Profit before share of associates & JVs and tax	(22.02)	(8.74)	Loss widened	(19.16)	Loss widened
Share of profit/(loss) of associates & JVs	(4.89)	(1.53)		(3.67)
Net profit for the period	(25.26)	(7.64)	Loss widened	(20.59)	Loss widened
Attributable to shareholders of the company	(22.28)	(6.47)	Loss widened	(18.02)	Loss widened
EPS, basic (₹)	(2.51)	(0.74)	Loss widened	(2.05)	Loss widened
Net margin (%)	-9.1	-3.1		-7.7

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY20	Q2 FY19	YoY	Q1 FY20	QoQ
Revenue from operations	173.71	161.67	+7.4%	170.89	+1.7%
Other income	2.36	2.80	−15.7%	2.45	−3.7%
Total income	176.07	164.47	+7.1%	173.34	+1.6%
Profit before tax	(5.02)	1.67	Turned loss	(3.41)	Loss widened
Net profit for the period	(3.47)	1.09	Turned loss	(2.01)	Loss widened
EPS, basic (₹)	(0.39)	0.12	Turned loss	(0.23)	Loss widened
Net margin (%)	-2.0	0.7		-1.2

Consolidated

Filed with BSE: 13 Nov 2019, 15:20 IST
Board meeting: 07 Nov 2019
Period: 01 Jul 2019 to 30 Sep 2019
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 13 Nov 2019, 15:20 IST
Board meeting: 07 Nov 2019
Period: 01 Jul 2019 to 30 Sep 2019
Review status: Unaudited
Source: XBRL filing on BSE